Recently, tocilizumab, a humanized recombinant mAb against the IL-6R, showed the potential to improve prognosis in IL-6-expressing lung cancer and recurrent epithelial ovarian cancer (61, 62). This evidence concerns the gene IL6 and lung carcinoma.